Alzheimer's disease (AD), the most common cause of dementia in older adults, despite decades of research, drug candidates and clinical trials, it remains a challenging condition, both from a biological and clinical perspective. Apart from palliative drugs, which only slow symptoms, there is no approved reversal therapy: the impact of AD is enormous on healthcare systems, and it is projected to grow with a progressively ageing population. While most of AD cases are idiopathic, i.e. without a clear causative factor, the production and following the accumulation of aberrant amyloid beta peptides in patients’ brains are considered as cornerstones of the disease and linked to the complex biochemical cascade, which is believed to start with excessive APP proteolytic cleavage by beta secretase (BACE1) enzyme.